MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Seres Therapeutics Company Profile (NASDAQ:MCRB)

Consensus Ratings for Seres Therapeutics (NASDAQ:MCRB) (?)
Ratings Breakdown: 1 Hold Rating(s), 7 Buy Rating(s)
Consensus Rating:Buy (Score: 2.88)
Consensus Price Target: $43.86 (55.03% upside)

Analysts' Ratings History for Seres Therapeutics (NASDAQ:MCRB)
Show:
DateFirmActionRatingPrice TargetActions
6/13/2016Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/29/2016Canaccord GenuityReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/19/2016FBR & Co.Reiterated RatingOutperform$40.00 -> $43.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/3/2016GuggenheimInitiated CoverageBuy$41.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/28/2016HC WainwrightReiterated RatingBuy$55.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/26/2016Leerink SwannLower Price TargetOutperform$60.00 -> $43.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/22/2016Goldman SachsLower Price Target$35.00 -> $34.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/22/2015Bank of AmericaUpgradeNeutral -> Buy$41.00 -> $41.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/25/2014 forward)
Earnings History for Seres Therapeutics (NASDAQ:MCRB)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016        
5/16/2016Q116($0.48)($0.50)$1.25 million$2.71 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2015Q315($0.32)($0.38)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015Q215($0.30)($1.45)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Seres Therapeutics (NASDAQ:MCRB)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.54)($0.54)($0.54)
Q2 20162($0.62)($0.24)($0.43)
Q3 20162($0.49)($0.20)($0.35)
Q4 20162($0.58)($0.11)($0.35)
(Data provided by Zacks Investment Research)
Dividend History for Seres Therapeutics (NASDAQ:MCRB)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Seres Therapeutics (NASDAQ:MCRB)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/2/2016David N CookEVPSell8,000$31.00$248,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/2/2016Roger PomerantzCEOSell74,049$32.52$2,408,073.48View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2016David N CookEVPSell16,000$29.43$470,880.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2016Roger PomerantzCEOSell70,951$30.51$2,164,715.01View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/25/2016Ventures Fund 2007 L FlagshipMajor ShareholderSell1,000,000$27.60$27,600,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/24/2016Roger PomerantzCEOSell9,801$30.00$294,030.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/6/2016Roger PomerantzCEOSell8,507$24.31$206,805.17View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/5/2016Roger PomerantzCEOSell59,325$26.13$1,550,162.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/3/2016Roger PomerantzCEOSell67,367$28.70$1,933,432.90View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/25/2016John G AuninsEVPSell18,640$31.94$595,361.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/7/2016David N CookEVPSell8,000$31.00$248,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/7/2016Roger PomerantzCEOSell9,212$30.00$276,360.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/4/2016David N CookEVPSell61,000$26.16$1,595,760.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/4/2016Eric D ShaffCFOSell6,568$28.85$189,486.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/4/2016Roger PomerantzCEOSell135,788$27.20$3,693,433.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/31/2016Eric D ShaffCFOSell7,663$26.30$201,536.90View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/28/2016Eric D ShaffCFOSell5,473$24.07$131,735.11View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/28/2016John G AuninsEVPSell9,390$23.89$224,327.10View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Seres Therapeutics (NASDAQ:MCRB)
DateHeadline
06/22/16 07:49 AMSeres Therapeutics Announces Collaboration with Massachusetts General Hospital to Identify Microbiome Therapeutics for Obesity and Metabolic Syndrome - [at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 22, 2016-- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics platform company, today announced a collaboration with Massachusetts General ...
06/20/16 12:19 PMSeres Therapeutics Presents New Data at ASM Microbe 2016, including Characterization of SER-262, the Rationally-Designed, Fermented Microbiome Therapeutic Candidate for Primary Clostridium difficile Infection - [at noodls] - - Initiation of a SER-262 Phase 1b study, a first ever for a synthetic microbiome therapeutic, is expected to begin in mid-2016 - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 20, 2016-- Seres Therapeutics, ...
06/17/16 03:41 PMSERES THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/15/16 05:04 PMCowen & Company Initiates Coverage on Seres Therapeutics Inc to Outperform - TheFounders Daily
06/11/16 07:56 AMNestle's Foray Into Medicines Could Add $10B in Revenue
06/11/16 07:56 AMCommit To Purchase Seres Therapeutics At $30, Earn 31.9% Annualized Using Options
06/10/16 08:01 AMCommit To Purchase Seres Therapeutics At $30, Earn 31.9% Annualized Using Options - Nasdaq
06/08/16 05:30 PMSERES THERAPEUTICS INC. (NASDAQ:MCRB) Financial Condition Compared to S&P 500 - CML News
06/06/16 08:49 AMInsiders Out, Institutional Investors In, Time To Buy Seres Therapeutics?
06/06/16 06:18 AMSeres Therapeutics Announces Research Collaboration with Mayo Clinic to Identify Microbiome Therapeutics for Primary Sclerosing Cholangitis, Non-Alcoholic Steatohepatitis (NASH) and Other Liver Diseases - [at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 6, 2016-- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics platform company, today announced that it has initiated a sponsored research ...
06/03/16 05:31 PMSeres Therapeutics Inc (MCRB) Stock Price Down 7.7% After Insider Selling - Let Me Know About This
06/03/16 07:53 AMSeres Therapeutics, Inc. (NASDAQ:MCRB) Trading Up – Insiders Are Selling - There has been some selling insider activity on Seres Therapeutics, Inc. (NASDAQ:MCRB) recently. Chief Scientific Officer & EVP David N. Cook sold 16,000 shares at an average price of $29.43 on Wed the 1st. That brings Cook’s holdings to $4,257,726 per ...
06/02/16 08:15 AMSeres Therapeutics to Present at Goldman Sachs 37th Annual Global Healthcare Conference - [at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 2, 2016-- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics platform company, today announced it will present at the Goldman Sachs 37 Annual ...
05/31/16 10:13 AMSeres Therapeutics Incorporated (NASDAQ:MCRB) Shorts Decreased by 8.01% After Short Covering - HNN - Seres Therapeutics Incorporated (NASDAQ:MCRB) Shorts Decreased by 8.01% After Short CoveringHNNThe short interest to Seres Therapeutics Incorporated's float is 18.46%. The stock increased 0.61% or $0.18 on May 27, hitting $29.46. About 182,069 shares traded hands. Seres Therapeutics Inc (NASDAQ:MCRB) has risen 2.54% since October 22, 2015 ...Seres Therapeutics, Inc. (NASDAQ:MCRB) Trading Up - Insiders Are SellingFinance DailyIs it Time to Cash in Profits on Seres Therapeutics, Inc. (NASDAQ:MCRB)Franklin IndependentSeres Health, Inc. (NASDAQ:MCRB) Broker Price Targets For The Coming WeekShare Trading NewsRisers & Fallersall 3 news articles »
05/31/16 10:13 AMTarget Check and Stock Performance Recap Seres Therapeutics Inc (NASDAQ:MCRB) - HNN - Target Check and Stock Performance Recap Seres Therapeutics Inc (NASDAQ:MCRB)HNNTracking stock performance from various views may help with share evaluation. Some investors might be more focused on short-term share action while others may prefer to view long-term performance. In recent session activity, Seres Therapeutics Inc ...and more »
05/31/16 10:13 AMStock Review and Earnings Check on Seres Therapeutics Inc (NASDAQ:MCRB) - HNN - Stock Review and Earnings Check on Seres Therapeutics Inc (NASDAQ:MCRB)HNNCompany earnings are a good way to evaluate the company profitability. Currently, sell-side analysts are expecting Seres Therapeutics Inc (NASDAQ:MCRB) to report quarterly EPS of $-0.43. The company's next earnings report is expected to be published ...and more »
05/28/16 12:04 PMSeres Therapeutics, Inc. (NASDAQ:MCRB) Trading Up - Insiders Are Selling - Finance Daily - Seres Therapeutics, Inc. (NASDAQ:MCRB) Trading Up - Insiders Are SellingFinance DailyThere has been some selling insider activity on Seres Therapeutics, Inc. (NASDAQ:MCRB) recently. Yesterday Director Noubar Afeyan disclosed the sale of 1,000,000 shares of MCRB stock. The shares were sold on May 25th for an average price of $27.60.Seres Health, Inc. (NASDAQ:MCRB) Updated Broker RatingsRisers & FallersAnalysts Offer Insights on Healthcare Companies: SAGE Therapeutics Inc (NASDAQ: SAGE), T2 Biosystems (NASDAQ ...Analyst Ratingsall 5 news articles »
05/25/16 01:29 PMStock Rating Review for Seres Therapeutics Inc (NASDAQ:MCRB) - Wall Street Hints and News - Stock Rating Review for Seres Therapeutics Inc (NASDAQ:MCRB)Wall Street Hints and NewsInvestors may choose to follow the views of professional Wall Street analysts that regularly track the company. Covering equity analysts presently have a consensus stock rating of 1 on shares of Seres Therapeutics Inc (NASDAQ:MCRB). Covering analysts ...and more »
05/24/16 01:11 PMEarnings Review and Stock Rundown for Seres Therapeutics Inc (NASDAQ:MCRB) - Wall Street Hints and News - Earnings Review and Stock Rundown for Seres Therapeutics Inc (NASDAQ:MCRB)Wall Street Hints and NewsInvestors and analysts will be paying close attention when the company posts earnings results. Earnings numbers can provide insight into a company's overall profitability. Covering equity analysts are expecting Seres Therapeutics Inc (NASDAQ:MCRB) to ...and more »
05/24/16 12:04 PMSERES THERAPEUTICS, INC. Financials -
05/23/16 04:52 PMSeres Therapeutics, Inc. – Value Analysis (NASDAQ:MCRB) : May 23, 2016 -
05/22/16 01:27 PMRevenue Update on Seres Therapeutics Inc(NASDAQ:MCRB) - Trade Calls - Revenue Update on Seres Therapeutics Inc(NASDAQ:MCRB)Trade CallsSeres Therapeutics Inc(NASDAQ:MCRB) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during Pre-market on May 16, 2016. Company reported revenue of $2.71M. Analysts estimated a revenue of $1.25M. Earnings per ...Analyst Recommendations On Seres Therapeutics Inc (NASDAQ:MCRB)News TribuneSeres Therapeutics Inc Just Recorded A Sigfniciant IncreaseThe PostStocks in Focus: Biostag (NASDAQ:BSTG), Seres Therapeutics (NASDAQ:MCRB), Celadon Group Inc. (NYSE:CGI ...Benchmark MonitorMarkets.coall 6 news articles »
05/20/16 07:03 AMSeres Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : MCRB-US : May 20, 2016 -
05/17/16 01:46 PMShare Recap and Earnings Focus on Seres Therapeutics Inc (NASDAQ:MCRB) - Wall Street Hints and News - Share Recap and Earnings Focus on Seres Therapeutics Inc (NASDAQ:MCRB)Wall Street Hints and NewsAnalysts and investors are usually very focused on company earnings numbers when they are released. Company earnings are a good way to evaluate the profitability of the company. Presently, covering analysts are anticipating Seres Therapeutics Inc ...and more »
05/17/16 01:46 PMAnalysts Offer Insights on Healthcare Companies: Seres Therapeutics Inc. (NASDAQ: MCRB), Global Blood ... - Analyst Ratings - Analysts Offer Insights on Healthcare Companies: Seres Therapeutics Inc. (NASDAQ: MCRB), Global Blood ...Analyst RatingsThere's a lot to be optimistic about in the Healthcare sector as 4 experts just weighed in on Seres Therapeutics Inc. (NASDAQ: MCRB), Global Blood Therapeutics Inc. (NASDAQ: GBT), Paratek Pharmaceuticals Inc. (NASDAQ: PRTK) and Trevena Inc.and more »
05/17/16 07:42 AMSeres Therapeutics to Present at the 2016 UBS Healthcare Conference - [at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 17, 2016-- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics platform company, today announced it will present at the UBS Global Healthcare ...
05/16/16 03:46 PMSERES THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report -
05/16/16 12:29 PMEdited Transcript of MCRB earnings conference call or presentation 16-May-16 12:30pm GMT -
05/16/16 07:30 AMSeres Therapeutics Inc Earnings Call scheduled for 8:30 am ET today -
05/16/16 06:32 AMSeres Therapeutics Announces Appointment of Thomas J. DesRosier as Chief Legal Officer and Executive Vice President - [at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 16, 2016-- Seres Therapeutics Inc. (NASDAQ:MCRB), a leading microbiome therapeutics company, announced today that it has appointed Thomas J. DesRosier as Chief Legal ...
05/16/16 06:32 AMSeres Therapeutics Reports First Quarter Financial Results and Provides Operational Progress Update - [at noodls] - SER-109 Phase 2 study enrollment complete; results expected in mid-2016 Academic collaborations further microbiome therapeutic leadership in immuno-oncology, rare genetic diseases and other indications ...
05/16/16 06:07 AMSeres Therapeutics reports 1Q loss -
05/12/16 12:46 PMNoteworthy Thursday Option Activity: UPS, MCRB, PANW - Below is a chart showing UPS’s trailing twelve month trading history, with the $92.50 strike highlighted in orange: Click here to find out Today’s Most Active Call & Put Options of the S&P 500 » Seres Therapeutics Inc (NASD: MCRB) saw options trading ...
05/12/16 06:17 AMSeres Therapeutics Announces Collaboration with University of Pennsylvania Researchers to Support the Development of Microbiome Therapeutics for Rare Genetic Metabolic Diseases and Inflammatory Bowel Disease - [at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 12, 2016-- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics platform company, today announced that it has entered into a multi-year collaboration ...
05/12/16 06:17 AMSeres Therapeutics Announces Broad Agreement with Memorial Sloan Kettering Cancer Center to Develop Microbiome Therapeutics for Hematopoietic Stem Cell Transplantation and Immuno-Oncology Treatment - [at noodls] - - Agreements provide IP license bolstering Company's strong patent portfolio - CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 12, 2016-- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics ...
05/12/16 06:01 AM7:01 am Seres Therapeutics enters into two seperate multi-year collaborations with the University of Pennsylvania & Memorial Sloan Kettering Cancer Center -
05/11/16 12:57 PMConsensus Rating Review for Seres Therapeutics Inc (NASDAQ:MCRB) - B.O.D.Y Confidential - Consensus Rating Review for Seres Therapeutics Inc (NASDAQ:MCRB)B.O.D.Y ConfidentialEquity research analysts currently have a consensus rating of 1 on shares of Seres Therapeutics Inc (NASDAQ:MCRB). Sell-side analysts will typically rate a company's stock based on extensive research. These ratings usually translate into a Buy, Sell, ...and more »
05/10/16 01:11 PMSeres Therapeutics, Inc. (NASDAQ:MCRB) Is Trading Up – Insiders Are Selling - Here is the rundown on market activity for Seres Therapeutics, Inc.. CTO John G. Aunins let go of 18,640 shares at an average price of $31.94 on April 25th. Aunins now owns $1,790,556 of stock as reported to the SEC. Yesterday Chief Scientific Officer ...
05/09/16 07:08 AMSeres Therapeutics to Host First Quarter 2016 Financial Results and Operational Progress Conference Call and Webcast on May 16, 2016 - [at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 9, 2016-- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics platform company, today announced that management will host a conference call ...
05/04/16 12:32 PMIt Seems Seres Therapeutics Inc Will Go Down. Have Another Big Decline - B.O.D.Y Confidential - It Seems Seres Therapeutics Inc Will Go Down. Have Another Big DeclineB.O.D.Y ConfidentialThe stock of Seres Therapeutics Inc (NASDAQ:MCRB) is a huge mover today! The stock decreased 6.63% or $1.97 during the last trading session, hitting $27.73. Seres Therapeutics Inc (NASDAQ:MCRB) has declined 19.97% since September 28, 2015 and ...Seres Therapeutics Announces Academic Collaborations to Support Development of Microbiome Therapeutics for ...Business Wire (press release)all 2 news articles »
05/04/16 12:32 PMAverage Analyst Rating for Seres Therapeutics Inc (NASDAQ:MCRB) - B.O.D.Y Confidential - Average Analyst Rating for Seres Therapeutics Inc (NASDAQ:MCRB)B.O.D.Y ConfidentialWall Street analysts have provided an average broker recommendation of 1 on Seres Therapeutics Inc (NASDAQ:MCRB) shares. The rating is determined by using the average of all analyst recommendations taken into consideration by Zacks Research.and more »
05/04/16 07:20 AMSeres Therapeutics Announces Academic Collaborations to Support Development of Microbiome Therapeutics for Inflammatory Bowel Disease - [at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 4, 2016-- Seres Therapeutics, Inc. (NASDAQ: MCRB), a leading microbiome therapeutics platform company, today announced it has entered into two separate research collaborations ...
05/03/16 07:10 AMSeres Therapeutics to Present at the Bank of America Merrill Lynch 2016 Health Care Conference - [at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 3, 2016-- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics platform company, today announced it will present at the Bank of America Merrill ...
05/02/16 01:41 PMSeres Therapeutics (MCRB) Achieves Target Enrollment of SER-109 Phase 2 Study - StreetInsider.com - Seres Therapeutics (MCRB) Achieves Target Enrollment of SER-109 Phase 2 StudyStreetInsider.comSeres Therapeutics, Inc. (NASDAQ: MCRB) announced today that the target enrollment of 87 patients has been achieved for its ongoing SER-109 Phase 2 clinical study. SER-109 is an oral, potential first-in-field microbiome therapeutic that has been ...Seres Therapeutics Incorporated (NASDAQ:MCRB) Sellers Covered 9.2% of Their ShortsFranklin Independentall 2 news articles »
05/02/16 07:10 AMSeres Therapeutics Announces Achievement of Target Enrollment of SER-109 Phase 2 Study for the Prevention of Recurrent Clostridium difficile Infection - [at noodls] - Phase 2 data expected in mid-2016 New SER-109 Expanded Access Program initiated at Phase 2 clinical sites CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 2, 2016-- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading ...
04/27/16 01:26 PMSeres Therapeutics Inc (NASDAQ:MCRB) Share Rating Recap - B.O.D.Y Confidential - Seres Therapeutics Inc (NASDAQ:MCRB) Share Rating RecapB.O.D.Y ConfidentialShares of Seres Therapeutics Inc (NASDAQ:MCRB) are tracked by analysts as well as crowd investors. Research from Beta Systems keeps track of crowd sourced sentiment and provides consensus stock ratings. The rating information comes mainly from ...and more »
04/22/16 01:27 PMSeres Therapeutics Inc (NASDAQ:MCRB) Analyst Rating Review - B.O.D.Y Confidential - Seres Therapeutics Inc (NASDAQ:MCRB) Analyst Rating ReviewB.O.D.Y ConfidentialCovering analysts typically give Buy, Sell and Hold recommendations along with guidance and company earnings projections. Currently, there are 6 analysts that have provided ratings for Seres Therapeutics Inc (NASDAQ:MCRB). 6 have rated the stock a ...and more »
04/22/16 01:27 PMSeres Therapeutics Inc (NASDAQ:MCRB) Reported Basic Consolidated EPS Of $-2.3279 - Investor Newswire - Seres Therapeutics Inc (NASDAQ:MCRB) Reported Basic Consolidated EPS Of $-2.3279Investor NewswireFrom the parent company, Seres Therapeutics Inc (NASDAQ:MCRB) obtained diluted EPS of $-2.3279 for the period ended 2015-12-31. On quarterly basis, the diluted EPS payment from the parent firm for the quarter ended 2015-12-31 was $-2.3279.
04/20/16 06:40 AMGut instinct leads Peninsula company to $42 million -
04/01/16 05:00 AMJim Cramer's Top Takeaways: Radius Health, Seres Therapeutics -
About Seres Therapeutics

Seres Therapeutics logoSeres Therapeutics, Inc. is a microbiome therapeutics platform company. The Company is engaged in developing a range of biological drugs, Ecobiotic microbiome therapeutics. It is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome in the human body. Its products include SER-109, which is designed to prevent further recurrences of Clostridium difficile infection, (CDI), a debilitating infection of the colon; SER-109; SER-262, and SER-155. It's SER-262 is a multi-strain Ecobiotic microbiome therapeutic to be used following antibiotic treatment of primary CDI to prevent an initial recurrence of CDI. The Company is developing SER-287 to treat ulcerative colitis. It is developing SER-155, which is an Ecobiotic microbiome therapeutic to treat enteric pathogens.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: MCRB
  • CUSIP:
Key Metrics:
  • Previous Close: $30.37
  • 50 Day Moving Average: $29.13
  • 200 Day Moving Average: $28.96
  • P/E Ratio: N/A
  • P/E Growth: -0.35
  • Market Cap: $1.12B
  • Current Quarter EPS Consensus Estimate: $-1.72 EPS
Additional Links:
Seres Therapeutics (NASDAQ:MCRB) Chart for Saturday, June, 25, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha